The Technical Analyst
N/A [N/A]
Exchange: N/A Sector: Healthcare
N/A Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.11% $7.75
Last updated: 16 May 2022 @ 12:18 pm
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ WORLD Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 299.95 mill |
| EPS: | -2.84 |
| P/E: | 0.000 |
| Earnings Date: | N/A |
| SharesOutstanding: | 38.70 mill |
| Avg Daily Volume: | 0.0454 mill |
| RATING 2022-05-13 |
|---|
| B+ |
| Buy |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | |||
|---|---|---|---|
| 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a |
| Ebit | |||
| Asset | n/a | ||
| Debt | n/a | n/a | n/a |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$33.15 (327.76%) $25.40 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $1.148 ( +/- 15.13%) Range: 6.44 - 8.74 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-02-18 | Rivera Victor | Buy | 130 000 | Stock Option (right to buy) |
| 2022-02-18 | Shakespeare William | Buy | 180 000 | Stock Option (right to buy) |
| 2022-02-18 | Dahms Bradford D. | Buy | 150 000 | Stock Option (right to buy) |
| 2022-02-18 | Dalgarno David | Buy | 130 000 | Stock Option (right to buy) |
| 2022-02-18 | Clackson Timothy P | Buy | 450 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 71.32 |
| Last 47 transactions |
| Buy: 38 360 388 | Sell: 4 142 508 |
Live Trading Signals (every 1 min)
Forecast
1: 12:14 - $7.72
Forecast 2: 13:04 - $7.59
Forecast 3: 13:44 - $7.71
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $7.75 (2.11% ) |
| Volume | 0.0088 mill |
| Avg. Vol. | 0.0454 mill |
| % of Avg. Vol | 19.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Latest Press Releases
2022-05-12 07:00:00 - Press Release
Theseus Pharmaceuticals Announces Business Highlights And Reports First Quarter 2022 Financial Results
The-630 phase 1/2 clinical trial actively enrolling patients with advanced gastrointestinal stromal tumors (gist); initial data expected in 1h 2023 on track to nominate development candidate for fourth-generation epidermal growth factor receptor (egfr) program targeting non-small cell lung cancer (nsclc) in q3 2022; ind expected in 2023 $237.0 million in cash, cash equivalents, and investments as of march 31, 2022, expected to fund operations into the second half of 2024 cambridge, mass. , may 12, 2022 /prnewswire/ -- theseus pharmaceuticals, inc. (nasdaq: thrx) (theseus or the company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the first quarter ended march 31, 2022.
2022-04-05 08:30:00 - Press Release
Theseus Pharmaceuticals To Participate Virtually In Needham Healthcare Conference
Cambridge, mass. , april 5, 2022 /prnewswire/ -- theseus pharmaceuticals, inc. (nasdaq: thrx) ("theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that it will participate in the 21st annual needham virtual healthcare conference, taking place april 11-14, 2022.
2022-03-10 07:00:00 - Press Release
Theseus Pharmaceuticals Announces Business Highlights And Reports Fourth Quarter And Full Year 2021 Financial Results
Cambridge, mass., march 10, 2022 /prnewswire/ -- theseus pharmaceuticals, inc. (nasdaq: thrx) (theseus or the company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the fourth quarter and full year ended december 31, 2021.
2022-02-02 07:30:00 - Press Release
Theseus Pharmaceuticals Receives U.s. Fda Orphan Drug Designation For The-630 For The Treatment Of Advanced Gastrointestinal Stromal Tumors (gist)
Cambridge, mass., feb. 2, 2022 /prnewswire/ -- theseus pharmaceuticals, inc. (theseus) (nasdaq: thrx), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the u.s. food and drug administration (fda) has granted orphan drug designation (odd) to the company's lead candidate the-630, a small-molecule oral pan-variant kit inhibitor, for the treatment of patients with advanced gastrointestinal stromal tumors (gist).
Latest News
2022-03-08 17:01:00 - PRNewsWire
Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting
CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the Company will present a poster highlighting the characterization of potent and selective next-generation EGFR inhibitors at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, Louisiana.
2022-02-09 07:30:00 - PRNewsWire
Theseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 9, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that Tim Clackson, Ph.D.
2022-01-18 14:56:30 - Stockmarketcom
Top Stocks To Invest In Right Now? 5 Health Care Stocks To Watch
2021-12-27 11:12:33 - Benzinga
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in programs and the reemergence of variant strains.